论文部分内容阅读
Ｓｕｌｐｅｒａｚｏｎｅ与头孢哌酮、头孢噻肟、头孢曲松及氨曲南对１０８３株１９９０～１９９２年临床分离致病菌的体外抗菌活性比较表明，对克雷白氏菌、阴沟肠杆菌、枸橼酸杆菌、沙雷氏菌、变形杆菌、绿脓杆菌、金葡菌、表皮葡萄球菌、粪链球菌、溶血性链球菌、肺炎球菌和流感杆菌，Ｓｕｌｐｅｒａｚｏｎｅ比头孢哌酮ＭＩＣ９０低２～８倍。对乙酸钙不动杆菌和厌氧菌，Ｓｕｌｐｅｒａｚｏｎｅ的抗菌作用比头孢哌酮显著增强，ＭＩＣ９０分别为１和４ｍｇ／Ｌ，比头孢哌酮分别降低１２８和８倍。Ｓｕｌｐｅｒａｚｏｎｅ对氨苄青霉素耐药（ＭＩＣ≥３２ｍｇ／Ｌ）的大肠杆菌和克雷白氏菌ＭＩＣ９０分别为１和４ｍｇ／Ｌ，优于头孢哌酮、头孢噻肟和头孢曲松。对５０％以上的头孢哌酮耐药菌（ＭＩＣ≥６４ｍｇ／Ｌ），Ｓｕｌｐｅｒａｚｏｎｅ增效达８倍以上。Ｓｕｌｐｅｒａｚｏｎｅ具有较强的杀菌作用，细菌接种量与培养基ｐＨ值对Ｓｕｌｐｅｒａｚｏｎｅ体外抗菌作用影响不显著。
In vitro antibacterial activity of Sulperazone with cefoperazone, cefotaxime, ceftriaxone and aztreonam on 1083 isolates from 1990 to 1992 showed that Klebsiella, Enterobacter cloacae, citric acid Bacillus, Serratia, Proteus, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus faecalis, Streptococcus hemolyticus, Streptococcus pneumoniae and Influenza bacilli, Sulperazone 2 to 8 times lower than cefoperazone MIC90. For Acinetobacter calcoaceticus and anaerobic bacteria, the antibacterial activity of Sulperazone was significantly enhanced compared to cefoperazone with MIC90 of 1 and 4 mg / L, 128 and 8 fold lower than cefoperazone respectively. Sulperazone was 1 and 4 mg / L against ampicillin-resistant (MIC ≥ 32 mg / L) Escherichia coli and Klebsiella sp., Respectively, better than cefoperazone, cefotaxime and ceftriaxone. For more than 50% of cefoperazone-resistant bacteria (MIC≥64mg / L), Sulperazone synergized more than 8 times. Sulperazone has a strong bactericidal effect, bacterial inoculum size and pH of the medium on Sulperazone in vitro antibacterial effect was not significant.